Cantor Fitzgerald lifted their target price on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) to $145.00 in a research note issued on Wednesday, StockRatingsNetwork.com reports. Cantor Fitzgerald’s price objective would indicate a potential upside of 27.41% from the company’s current price.
A number of other firms have also recently commented on JAZZ. Analysts at Barclays raised their price target on shares of Jazz Pharmaceuticals Plc from $112.00 to $130.00 in a research note to investors on Monday, November 25th. They now have an “overweight” rating on the stock. Separately, analysts at FBR Capital Markets reiterated an “outperform” rating on shares of Jazz Pharmaceuticals Plc in a research note to investors on Monday, November 25th. They now have a $198.00 price target on the stock, up previously from $105.00. Finally, analysts at R. F. Lafferty raised their price target on shares of Jazz Pharmaceuticals Plc from $102.00 to $118.00 in a research note to investors on Wednesday, November 13th. They now have a “buy” rating on the stock. Fifteen investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $104.88.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded up 1.24% during mid-day trading on Wednesday, hitting $115.2263. The stock had a trading volume of 239,621 shares. Jazz Pharmaceuticals Plc has a 52-week low of $48.71 and a 52-week high of $118.80. The stock’s 50-day moving average is $99.83 and its 200-day moving average is $83.10. The company has a market cap of $6.659 billion and a P/E ratio of 19.34.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.78 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.67 by $0.11. The company had revenue of $232.20 million for the quarter, compared to the consensus estimate of $227.38 million. During the same quarter in the prior year, the company posted $1.29 earnings per share. The company’s quarterly revenue was up 32.3% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals Plc will post $6.37 earnings per share for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.